Patient demographics within each study and the combined data set*
| COMMIT | Canadian multicentre | Transient ATI | IMM withdrawal | Combined | |
|---|---|---|---|---|---|
| Patients | |||||
| Patients—no. | 49 | 327 | 25 | 82 | 483 |
| Men—no. (%) | 28 (57) | 157 (48) | 11 (44) | 40 (49) | 236 (49) |
| Age at diagnosis | 29.5±13.3 | 29.3±13.2 | 26.8±11.6 | 25.5±11.3 | 28.5±12.9 |
| Age at first sample collection | 39.0±14.0 | 39.9±12.9 | 40.3±12.7 | 35.7±13.8 | 39.1±13.2 |
| Age at first infliximab | 38.6±14.1 | 38.5±13.0 | 39.9±12.5 | 33.7±13.8 | 37.7±13.3 |
| Patients ever IFX ≥3 μg/mL—no. (%) | 44 (90) | 237 (73) | 15 (60) | 75 (92) | 371 (77) |
| Patients ever ATI positive—no. (%) | 9 (18) | 73 (22) | 23 (92) | 12 (15) | 117 (24) |
| Patients ever receiving MTX—no. (%) | 23 (47) | 30 (9) | 9 (36) | 23 (28) | 85 (18) |
| Patients ever receiving AZA—no. (%) | 0 (0) | 81 (25) | 0 (0) | 59 (72) | 140 (29) |
| Serum samples | |||||
| Serum samples—no. | 169 | 637 | 314 | 367 | 1487 |
| Samples per subject† | 4 (1–4) | 2 (1–2) | 11 (2–26) | 4 (1–13) | 2 (1–26) |
| Time between first infliximab and sample—months† | 7 (6.5–9) | 17 (11–26) | 17 (9–40) | 24 (17–50) | 17 (9–29) |
| Serum samples IFX ≥3 μg/mL—no. (%) | 135 (80) | 417 (66) | 102 (33) | 295 (80) | 949 (64) |
| Serum samples ATI positive—no. (%) | 19 (11) | 115 (18) | 183 (58) | 36 (10) | 353 (24) |
| CRP—mg/L | 5.9±11.1 | 11.2±22.9 | 24.4±32.5 | 8.5±13.8 | 12.6±23.2 |
| CRP†—mg/L | 2.1 (0.8–6.2) | 3.0 (0.8–10.0) | 11.7 (3.1–29.7) | 2.4 (0.7–9.7) | 3.6 (1.0–12.7) |
*Mean±SD.
† Values are median and IQR.
ATI, antibodies to infliximab; AZA, azathioprine; CRP, C-reactive protein; IFX, infliximab; IMM, immunosuppressive; MTX, methotrexate.